Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (Nasdaq: MLYS) priced an underwritten public offering of 5,660,378 shares of common stock at $26.50 per share, for expected gross proceeds of about $150 million before expenses.
Net proceeds will help fund a $200 million upfront payment to repurchase a royalty obligation under a Tanabe Pharma license. The offering should close on or about June 4, 2026, subject to customary conditions. Earlier the company entered into a $500 million committed debt facility with funds managed by Pharmakon Advisors.
Positive
- Common stock offering expected to raise about $150 million gross proceeds
- Shares priced at $26.50, providing defined equity capital terms
- Net proceeds earmarked to help fund $200 million royalty repurchase payment
- $500 million committed debt facility expands available financing capacity
Negative
- Issuance of 5,660,378 new shares implies equity dilution for existing holders
- Offering proceeds subject to underwriting discounts, commissions and expenses reducing net cash
- Transaction closing remains subject to customary closing conditions, adding some execution risk
Details
News Market Reaction – MLYS
On Jun 3, the day this news came out, MLYS closed 13.14% below the previous close. That session’s volume was 6.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jun 3 session.
Key Figures
- Offering size
- $150.0 million
- Gross proceeds from underwritten common stock offering
- Shares offered
- 5,660,378 shares
- Common stock in current underwritten offering
- Offering price
- $26.50 per share
- Price for current common stock offering
- Upfront payment
- $200.0 million
- Portion of royalty repurchase upfront payment to Tanabe Pharma
- Debt facility
- $500 million
- Committed debt facility with funds managed by Pharmakon Advisors
Previous Offering Reports
-
Closed upsized offering raising $287.5M with full over-allotment exercise.
-
Priced upsized $250.0M offering at $25.50 per share.
-
Proposed $175.0M offering plus $26.25M underwriter option.
-
Closed sale of additional shares; total gross proceeds about $201.2M.
-
Priced $175.0M offering of 12,962,962 shares at $13.50.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten offering financial
royalty obligation financial
license agreement regulatory
committed debt facility financial
shelf registration statement regulatory
prospectus supplement regulatory
book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of
BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the offering.
Mineralys intends to use the net proceeds from the offering to fund a portion of the
The securities described above are being offered by Mineralys pursuant to a shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212-902-9316, or via email: prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the completion of the proposed offering and the anticipated use of proceeds therefrom. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Mineralys’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the proposed offering, and the other risks described in Mineralys’ filings with the SEC, including under the heading “Risk Factors” in Mineralys’ most recent Annual Report on Form 10-K and any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CONTACTS
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.